nodes	percent_of_prediction	percent_of_DWPC	metapath
Rocuronium—SLC22A1—prostate cancer	0.477	1	CbGaD
Rocuronium—SLCO1A2—Estrone—prostate cancer	0.119	0.31	CbGbCtD
Rocuronium—SLCO1A2—Conjugated Estrogens—prostate cancer	0.0782	0.203	CbGbCtD
Rocuronium—SLCO1A2—Estradiol—prostate cancer	0.0686	0.178	CbGbCtD
Rocuronium—SLC22A1—Estradiol—prostate cancer	0.0605	0.157	CbGbCtD
Rocuronium—SLCO1A2—Prednisone—prostate cancer	0.059	0.153	CbGbCtD
Rocuronium—Vecuronium—SLC22A1—prostate cancer	0.00189	0.54	CrCbGaD
Rocuronium—Pancuronium—SLC22A1—prostate cancer	0.00161	0.459	CrCbGaD
Rocuronium—Asthma—Estrone—prostate cancer	0.00158	0.0176	CcSEcCtD
Rocuronium—Asthma—Estradiol valerate/Dienogest—prostate cancer	0.00138	0.0154	CcSEcCtD
Rocuronium—Muscular weakness—Degarelix—prostate cancer	0.00134	0.0149	CcSEcCtD
Rocuronium—Electrocardiogram abnormal—Mitoxantrone—prostate cancer	0.00132	0.0148	CcSEcCtD
Rocuronium—Cardiovascular disorder—Conjugated Estrogens—prostate cancer	0.00132	0.0148	CcSEcCtD
Rocuronium—Arrhythmia—Abiraterone—prostate cancer	0.00115	0.0128	CcSEcCtD
Rocuronium—Muscular weakness—Bicalutamide—prostate cancer	0.00108	0.0121	CcSEcCtD
Rocuronium—Cardiovascular disorder—Estradiol—prostate cancer	0.00106	0.0118	CcSEcCtD
Rocuronium—Asthma—Bicalutamide—prostate cancer	0.00106	0.0118	CcSEcCtD
Rocuronium—Hypertension—Abiraterone—prostate cancer	0.000964	0.0108	CcSEcCtD
Rocuronium—Arrhythmia—Degarelix—prostate cancer	0.000935	0.0105	CcSEcCtD
Rocuronium—Anaphylactic shock—Estrone—prostate cancer	0.000897	0.01	CcSEcCtD
Rocuronium—Arrhythmia—Cabazitaxel—prostate cancer	0.000881	0.00985	CcSEcCtD
Rocuronium—Hypertension—Nilutamide—prostate cancer	0.000881	0.00985	CcSEcCtD
Rocuronium—Hypertension—Flutamide—prostate cancer	0.000877	0.0098	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Conjugated Estrogens—prostate cancer	0.000871	0.00973	CcSEcCtD
Rocuronium—Apnoea—Etoposide—prostate cancer	0.00085	0.0095	CcSEcCtD
Rocuronium—Cardiovascular disorder—Etoposide—prostate cancer	0.00082	0.00916	CcSEcCtD
Rocuronium—Shock—Nilutamide—prostate cancer	0.000819	0.00916	CcSEcCtD
Rocuronium—Hypertension—Degarelix—prostate cancer	0.000787	0.0088	CcSEcCtD
Rocuronium—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.000783	0.00875	CcSEcCtD
Rocuronium—Arrhythmia—Bicalutamide—prostate cancer	0.000756	0.00845	CcSEcCtD
Rocuronium—Anaphylactic shock—Degarelix—prostate cancer	0.000744	0.00832	CcSEcCtD
Rocuronium—Hypertension—Cabazitaxel—prostate cancer	0.000741	0.00829	CcSEcCtD
Rocuronium—Myopathy—Prednisone—prostate cancer	0.000736	0.00823	CcSEcCtD
Rocuronium—Asthma—Conjugated Estrogens—prostate cancer	0.000728	0.00814	CcSEcCtD
Rocuronium—Bronchospasm—Conjugated Estrogens—prostate cancer	0.000717	0.00801	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Estradiol—prostate cancer	0.000697	0.00779	CcSEcCtD
Rocuronium—Hypotension—Degarelix—prostate cancer	0.000695	0.00777	CcSEcCtD
Rocuronium—Tachycardia—Cabazitaxel—prostate cancer	0.000684	0.00765	CcSEcCtD
Rocuronium—Pruritus—Estramustine—prostate cancer	0.000664	0.00742	CcSEcCtD
Rocuronium—Hypotension—Cabazitaxel—prostate cancer	0.000655	0.00732	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Mitoxantrone—prostate cancer	0.000649	0.00726	CcSEcCtD
Rocuronium—Hypertension—Bicalutamide—prostate cancer	0.000636	0.00711	CcSEcCtD
Rocuronium—Pruritus—Estrone—prostate cancer	0.000634	0.00709	CcSEcCtD
Rocuronium—Respiratory failure—Docetaxel—prostate cancer	0.00061	0.00681	CcSEcCtD
Rocuronium—Vomiting—Estramustine—prostate cancer	0.000597	0.00667	CcSEcCtD
Rocuronium—Rash—Estramustine—prostate cancer	0.000592	0.00661	CcSEcCtD
Rocuronium—Shock—Bicalutamide—prostate cancer	0.000591	0.00661	CcSEcCtD
Rocuronium—Dermatitis—Estramustine—prostate cancer	0.000591	0.00661	CcSEcCtD
Rocuronium—Pruritus—Nilutamide—prostate cancer	0.000589	0.00659	CcSEcCtD
Rocuronium—Pruritus—Flutamide—prostate cancer	0.000587	0.00656	CcSEcCtD
Rocuronium—Asthma—Estradiol—prostate cancer	0.000583	0.00652	CcSEcCtD
Rocuronium—Paralysis—Epirubicin—prostate cancer	0.000581	0.0065	CcSEcCtD
Rocuronium—Vomiting—Abiraterone—prostate cancer	0.00058	0.00648	CcSEcCtD
Rocuronium—Hiccups—Capecitabine—prostate cancer	0.00058	0.00648	CcSEcCtD
Rocuronium—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000577	0.00644	CcSEcCtD
Rocuronium—Rash—Abiraterone—prostate cancer	0.000575	0.00642	CcSEcCtD
Rocuronium—Dermatitis—Abiraterone—prostate cancer	0.000574	0.00642	CcSEcCtD
Rocuronium—Bronchospasm—Estradiol—prostate cancer	0.000573	0.00641	CcSEcCtD
Rocuronium—Vomiting—Estrone—prostate cancer	0.00057	0.00637	CcSEcCtD
Rocuronium—Rash—Estrone—prostate cancer	0.000565	0.00632	CcSEcCtD
Rocuronium—Dermatitis—Estrone—prostate cancer	0.000565	0.00631	CcSEcCtD
Rocuronium—Nausea—Estramustine—prostate cancer	0.000558	0.00623	CcSEcCtD
Rocuronium—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000554	0.00619	CcSEcCtD
Rocuronium—Hypersensitivity—Degarelix—prostate cancer	0.000548	0.00613	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Etoposide—prostate cancer	0.00054	0.00604	CcSEcCtD
Rocuronium—Paralysis—Doxorubicin—prostate cancer	0.000538	0.00601	CcSEcCtD
Rocuronium—Nausea—Estrone—prostate cancer	0.000533	0.00595	CcSEcCtD
Rocuronium—Vomiting—Nilutamide—prostate cancer	0.00053	0.00592	CcSEcCtD
Rocuronium—Vomiting—Flutamide—prostate cancer	0.000527	0.00589	CcSEcCtD
Rocuronium—Pruritus—Degarelix—prostate cancer	0.000526	0.00588	CcSEcCtD
Rocuronium—Arrhythmia—Goserelin—prostate cancer	0.000526	0.00588	CcSEcCtD
Rocuronium—Rash—Nilutamide—prostate cancer	0.000525	0.00587	CcSEcCtD
Rocuronium—Dermatitis—Nilutamide—prostate cancer	0.000525	0.00586	CcSEcCtD
Rocuronium—Rash—Flutamide—prostate cancer	0.000523	0.00584	CcSEcCtD
Rocuronium—Dermatitis—Flutamide—prostate cancer	0.000522	0.00584	CcSEcCtD
Rocuronium—Arrhythmia—Conjugated Estrogens—prostate cancer	0.000521	0.00582	CcSEcCtD
Rocuronium—Hypersensitivity—Cabazitaxel—prostate cancer	0.000516	0.00577	CcSEcCtD
Rocuronium—Hiccups—Prednisone—prostate cancer	0.000516	0.00577	CcSEcCtD
Rocuronium—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000498	0.00556	CcSEcCtD
Rocuronium—Nausea—Nilutamide—prostate cancer	0.000495	0.00553	CcSEcCtD
Rocuronium—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000493	0.00551	CcSEcCtD
Rocuronium—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000493	0.00551	CcSEcCtD
Rocuronium—Nausea—Flutamide—prostate cancer	0.000492	0.0055	CcSEcCtD
Rocuronium—Vomiting—Degarelix—prostate cancer	0.000473	0.00529	CcSEcCtD
Rocuronium—Rash—Degarelix—prostate cancer	0.000469	0.00524	CcSEcCtD
Rocuronium—Dermatitis—Degarelix—prostate cancer	0.000469	0.00524	CcSEcCtD
Rocuronium—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000465	0.0052	CcSEcCtD
Rocuronium—Cardiovascular disorder—Epirubicin—prostate cancer	0.000459	0.00514	CcSEcCtD
Rocuronium—Vomiting—Cabazitaxel—prostate cancer	0.000446	0.00498	CcSEcCtD
Rocuronium—Bronchospasm—Etoposide—prostate cancer	0.000444	0.00497	CcSEcCtD
Rocuronium—Hypersensitivity—Bicalutamide—prostate cancer	0.000443	0.00495	CcSEcCtD
Rocuronium—Hypertension—Goserelin—prostate cancer	0.000442	0.00495	CcSEcCtD
Rocuronium—Nausea—Degarelix—prostate cancer	0.000442	0.00494	CcSEcCtD
Rocuronium—Pruritus—Bicalutamide—prostate cancer	0.000425	0.00475	CcSEcCtD
Rocuronium—Cardiovascular disorder—Doxorubicin—prostate cancer	0.000425	0.00475	CcSEcCtD
Rocuronium—Anaphylactic shock—Goserelin—prostate cancer	0.000418	0.00467	CcSEcCtD
Rocuronium—Nausea—Cabazitaxel—prostate cancer	0.000416	0.00465	CcSEcCtD
Rocuronium—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000414	0.00463	CcSEcCtD
Rocuronium—Shock—Goserelin—prostate cancer	0.000411	0.0046	CcSEcCtD
Rocuronium—Tachycardia—Goserelin—prostate cancer	0.000408	0.00456	CcSEcCtD
Rocuronium—Shock—Conjugated Estrogens—prostate cancer	0.000408	0.00456	CcSEcCtD
Rocuronium—Tachycardia—Conjugated Estrogens—prostate cancer	0.000404	0.00452	CcSEcCtD
Rocuronium—Hiccups—Epirubicin—prostate cancer	0.000404	0.00451	CcSEcCtD
Rocuronium—Hypotension—Goserelin—prostate cancer	0.000391	0.00437	CcSEcCtD
Rocuronium—Arrhythmia—Mitoxantrone—prostate cancer	0.000388	0.00434	CcSEcCtD
Rocuronium—Hypotension—Conjugated Estrogens—prostate cancer	0.000387	0.00433	CcSEcCtD
Rocuronium—Vomiting—Bicalutamide—prostate cancer	0.000382	0.00427	CcSEcCtD
Rocuronium—Rash—Bicalutamide—prostate cancer	0.000379	0.00424	CcSEcCtD
Rocuronium—Dermatitis—Bicalutamide—prostate cancer	0.000379	0.00423	CcSEcCtD
Rocuronium—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000374	0.00418	CcSEcCtD
Rocuronium—Hiccups—Doxorubicin—prostate cancer	0.000374	0.00418	CcSEcCtD
Rocuronium—Muscular weakness—Capecitabine—prostate cancer	0.000371	0.00415	CcSEcCtD
Rocuronium—Bronchospasm—Docetaxel—prostate cancer	0.000369	0.00413	CcSEcCtD
Rocuronium—Asthma—Capecitabine—prostate cancer	0.000364	0.00406	CcSEcCtD
Rocuronium—Pruritus—Ethinyl Estradiol—prostate cancer	0.00036	0.00402	CcSEcCtD
Rocuronium—Bronchospasm—Capecitabine—prostate cancer	0.000358	0.004	CcSEcCtD
Rocuronium—Nausea—Bicalutamide—prostate cancer	0.000357	0.00399	CcSEcCtD
Rocuronium—Hypertension—Estradiol—prostate cancer	0.000351	0.00392	CcSEcCtD
Rocuronium—Anaphylactic shock—Estradiol—prostate cancer	0.000332	0.00371	CcSEcCtD
Rocuronium—Muscular weakness—Prednisone—prostate cancer	0.00033	0.00369	CcSEcCtD
Rocuronium—Hypertension—Mitoxantrone—prostate cancer	0.000327	0.00365	CcSEcCtD
Rocuronium—Shock—Estradiol—prostate cancer	0.000326	0.00365	CcSEcCtD
Rocuronium—Tachycardia—Estradiol—prostate cancer	0.000324	0.00362	CcSEcCtD
Rocuronium—Vomiting—Ethinyl Estradiol—prostate cancer	0.000323	0.00361	CcSEcCtD
Rocuronium—Rash—Ethinyl Estradiol—prostate cancer	0.00032	0.00358	CcSEcCtD
Rocuronium—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00032	0.00358	CcSEcCtD
Rocuronium—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000309	0.00345	CcSEcCtD
Rocuronium—Hypersensitivity—Goserelin—prostate cancer	0.000308	0.00344	CcSEcCtD
Rocuronium—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000305	0.00341	CcSEcCtD
Rocuronium—Shock—Mitoxantrone—prostate cancer	0.000304	0.0034	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Epirubicin—prostate cancer	0.000303	0.00338	CcSEcCtD
Rocuronium—Nausea—Ethinyl Estradiol—prostate cancer	0.000302	0.00337	CcSEcCtD
Rocuronium—Tachycardia—Mitoxantrone—prostate cancer	0.000302	0.00337	CcSEcCtD
Rocuronium—Pruritus—Goserelin—prostate cancer	0.000296	0.00331	CcSEcCtD
Rocuronium—Pruritus—Conjugated Estrogens—prostate cancer	0.000293	0.00328	CcSEcCtD
Rocuronium—Hypotension—Mitoxantrone—prostate cancer	0.000289	0.00323	CcSEcCtD
Rocuronium—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.00028	0.00313	CcSEcCtD
Rocuronium—Hypertension—Etoposide—prostate cancer	0.000272	0.00304	CcSEcCtD
Rocuronium—Arrhythmia—Docetaxel—prostate cancer	0.000269	0.003	CcSEcCtD
Rocuronium—Vomiting—Goserelin—prostate cancer	0.000266	0.00297	CcSEcCtD
Rocuronium—Rash—Goserelin—prostate cancer	0.000264	0.00295	CcSEcCtD
Rocuronium—Dermatitis—Goserelin—prostate cancer	0.000263	0.00294	CcSEcCtD
Rocuronium—Vomiting—Conjugated Estrogens—prostate cancer	0.000263	0.00294	CcSEcCtD
Rocuronium—Rash—Conjugated Estrogens—prostate cancer	0.000261	0.00292	CcSEcCtD
Rocuronium—Dermatitis—Conjugated Estrogens—prostate cancer	0.000261	0.00292	CcSEcCtD
Rocuronium—Arrhythmia—Capecitabine—prostate cancer	0.00026	0.00291	CcSEcCtD
Rocuronium—Muscular weakness—Epirubicin—prostate cancer	0.000258	0.00289	CcSEcCtD
Rocuronium—Anaphylactic shock—Etoposide—prostate cancer	0.000257	0.00287	CcSEcCtD
Rocuronium—Asthma—Epirubicin—prostate cancer	0.000253	0.00283	CcSEcCtD
Rocuronium—Tachycardia—Etoposide—prostate cancer	0.000251	0.0028	CcSEcCtD
Rocuronium—Nausea—Goserelin—prostate cancer	0.000248	0.00278	CcSEcCtD
Rocuronium—Nausea—Conjugated Estrogens—prostate cancer	0.000246	0.00275	CcSEcCtD
Rocuronium—Hypersensitivity—Estradiol—prostate cancer	0.000244	0.00273	CcSEcCtD
Rocuronium—Hypotension—Etoposide—prostate cancer	0.00024	0.00268	CcSEcCtD
Rocuronium—Muscular weakness—Doxorubicin—prostate cancer	0.000239	0.00267	CcSEcCtD
Rocuronium—Pruritus—Estradiol—prostate cancer	0.000235	0.00262	CcSEcCtD
Rocuronium—Asthma—Doxorubicin—prostate cancer	0.000234	0.00262	CcSEcCtD
Rocuronium—Arrhythmia—Prednisone—prostate cancer	0.000232	0.00259	CcSEcCtD
Rocuronium—Hypersensitivity—Mitoxantrone—prostate cancer	0.000228	0.00254	CcSEcCtD
Rocuronium—Hypertension—Docetaxel—prostate cancer	0.000226	0.00253	CcSEcCtD
Rocuronium—Hypertension—Capecitabine—prostate cancer	0.000219	0.00244	CcSEcCtD
Rocuronium—Anaphylactic shock—Docetaxel—prostate cancer	0.000214	0.00239	CcSEcCtD
Rocuronium—Vomiting—Estradiol—prostate cancer	0.000211	0.00236	CcSEcCtD
Rocuronium—Shock—Docetaxel—prostate cancer	0.00021	0.00235	CcSEcCtD
Rocuronium—Rash—Estradiol—prostate cancer	0.000209	0.00234	CcSEcCtD
Rocuronium—Dermatitis—Estradiol—prostate cancer	0.000209	0.00233	CcSEcCtD
Rocuronium—Tachycardia—Docetaxel—prostate cancer	0.000208	0.00233	CcSEcCtD
Rocuronium—Shock—Capecitabine—prostate cancer	0.000203	0.00227	CcSEcCtD
Rocuronium—Tachycardia—Capecitabine—prostate cancer	0.000202	0.00226	CcSEcCtD
Rocuronium—Hypotension—Docetaxel—prostate cancer	0.0002	0.00223	CcSEcCtD
Rocuronium—Nausea—Estradiol—prostate cancer	0.000197	0.0022	CcSEcCtD
Rocuronium—Vomiting—Mitoxantrone—prostate cancer	0.000196	0.0022	CcSEcCtD
Rocuronium—Hypertension—Prednisone—prostate cancer	0.000195	0.00218	CcSEcCtD
Rocuronium—Rash—Mitoxantrone—prostate cancer	0.000195	0.00218	CcSEcCtD
Rocuronium—Dermatitis—Mitoxantrone—prostate cancer	0.000195	0.00218	CcSEcCtD
Rocuronium—Hypotension—Capecitabine—prostate cancer	0.000193	0.00216	CcSEcCtD
Rocuronium—Hypersensitivity—Etoposide—prostate cancer	0.000189	0.00212	CcSEcCtD
Rocuronium—Anaphylactic shock—Prednisone—prostate cancer	0.000184	0.00206	CcSEcCtD
Rocuronium—Nausea—Mitoxantrone—prostate cancer	0.000183	0.00205	CcSEcCtD
Rocuronium—Pruritus—Etoposide—prostate cancer	0.000182	0.00203	CcSEcCtD
Rocuronium—Shock—Prednisone—prostate cancer	0.000181	0.00203	CcSEcCtD
Rocuronium—Arrhythmia—Epirubicin—prostate cancer	0.000181	0.00202	CcSEcCtD
Rocuronium—Tachycardia—Prednisone—prostate cancer	0.00018	0.00201	CcSEcCtD
Rocuronium—Arrhythmia—Doxorubicin—prostate cancer	0.000168	0.00187	CcSEcCtD
Rocuronium—Vomiting—Etoposide—prostate cancer	0.000163	0.00183	CcSEcCtD
Rocuronium—Rash—Etoposide—prostate cancer	0.000162	0.00181	CcSEcCtD
Rocuronium—Dermatitis—Etoposide—prostate cancer	0.000162	0.00181	CcSEcCtD
Rocuronium—Hypersensitivity—Docetaxel—prostate cancer	0.000157	0.00176	CcSEcCtD
Rocuronium—Nausea—Etoposide—prostate cancer	0.000153	0.00171	CcSEcCtD
Rocuronium—Hypertension—Epirubicin—prostate cancer	0.000152	0.0017	CcSEcCtD
Rocuronium—Hypersensitivity—Capecitabine—prostate cancer	0.000152	0.0017	CcSEcCtD
Rocuronium—Pruritus—Docetaxel—prostate cancer	0.000151	0.00169	CcSEcCtD
Rocuronium—Pruritus—Capecitabine—prostate cancer	0.000146	0.00163	CcSEcCtD
Rocuronium—Anaphylactic shock—Epirubicin—prostate cancer	0.000144	0.00161	CcSEcCtD
Rocuronium—Shock—Epirubicin—prostate cancer	0.000142	0.00158	CcSEcCtD
Rocuronium—Hypertension—Doxorubicin—prostate cancer	0.000141	0.00158	CcSEcCtD
Rocuronium—Tachycardia—Epirubicin—prostate cancer	0.000141	0.00157	CcSEcCtD
Rocuronium—Vomiting—Docetaxel—prostate cancer	0.000136	0.00152	CcSEcCtD
Rocuronium—Hypersensitivity—Prednisone—prostate cancer	0.000136	0.00152	CcSEcCtD
Rocuronium—Rash—Docetaxel—prostate cancer	0.000135	0.0015	CcSEcCtD
Rocuronium—Hypotension—Epirubicin—prostate cancer	0.000135	0.0015	CcSEcCtD
Rocuronium—Dermatitis—Docetaxel—prostate cancer	0.000135	0.0015	CcSEcCtD
Rocuronium—Anaphylactic shock—Doxorubicin—prostate cancer	0.000133	0.00149	CcSEcCtD
Rocuronium—Vomiting—Capecitabine—prostate cancer	0.000131	0.00147	CcSEcCtD
Rocuronium—Shock—Doxorubicin—prostate cancer	0.000131	0.00147	CcSEcCtD
Rocuronium—Rash—Capecitabine—prostate cancer	0.00013	0.00146	CcSEcCtD
Rocuronium—Pruritus—Prednisone—prostate cancer	0.00013	0.00146	CcSEcCtD
Rocuronium—Dermatitis—Capecitabine—prostate cancer	0.00013	0.00146	CcSEcCtD
Rocuronium—Tachycardia—Doxorubicin—prostate cancer	0.00013	0.00145	CcSEcCtD
Rocuronium—Nausea—Docetaxel—prostate cancer	0.000127	0.00142	CcSEcCtD
Rocuronium—Hypotension—Doxorubicin—prostate cancer	0.000125	0.00139	CcSEcCtD
Rocuronium—Nausea—Capecitabine—prostate cancer	0.000123	0.00137	CcSEcCtD
Rocuronium—Vomiting—Prednisone—prostate cancer	0.000117	0.00131	CcSEcCtD
Rocuronium—Rash—Prednisone—prostate cancer	0.000116	0.0013	CcSEcCtD
Rocuronium—Dermatitis—Prednisone—prostate cancer	0.000116	0.0013	CcSEcCtD
Rocuronium—Nausea—Prednisone—prostate cancer	0.000109	0.00122	CcSEcCtD
Rocuronium—Hypersensitivity—Epirubicin—prostate cancer	0.000106	0.00119	CcSEcCtD
Rocuronium—Pruritus—Epirubicin—prostate cancer	0.000102	0.00114	CcSEcCtD
Rocuronium—Hypersensitivity—Doxorubicin—prostate cancer	9.82e-05	0.0011	CcSEcCtD
Rocuronium—Pruritus—Doxorubicin—prostate cancer	9.43e-05	0.00105	CcSEcCtD
Rocuronium—Vomiting—Epirubicin—prostate cancer	9.16e-05	0.00102	CcSEcCtD
Rocuronium—Rash—Epirubicin—prostate cancer	9.08e-05	0.00102	CcSEcCtD
Rocuronium—Dermatitis—Epirubicin—prostate cancer	9.07e-05	0.00101	CcSEcCtD
Rocuronium—Nausea—Epirubicin—prostate cancer	8.56e-05	0.000956	CcSEcCtD
Rocuronium—Vomiting—Doxorubicin—prostate cancer	8.47e-05	0.000947	CcSEcCtD
Rocuronium—Rash—Doxorubicin—prostate cancer	8.4e-05	0.000939	CcSEcCtD
Rocuronium—Dermatitis—Doxorubicin—prostate cancer	8.4e-05	0.000938	CcSEcCtD
Rocuronium—Nausea—Doxorubicin—prostate cancer	7.92e-05	0.000885	CcSEcCtD
Rocuronium—SLC22A1—Neuronal System—MDM2—prostate cancer	1.76e-05	0.0004	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.73e-05	0.000393	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—GNG5—prostate cancer	1.73e-05	0.000392	CbGpPWpGaD
Rocuronium—CHRM2—G alpha (i) signalling events—CXCL8—prostate cancer	1.73e-05	0.000392	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—HSD3B1—prostate cancer	1.72e-05	0.000391	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—SLC22A3—prostate cancer	1.72e-05	0.000391	CbGpPWpGaD
Rocuronium—CHRM2—Regulation of Actin Cytoskeleton—KRAS—prostate cancer	1.72e-05	0.00039	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—HPGDS—prostate cancer	1.68e-05	0.000381	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP2C19—prostate cancer	1.67e-05	0.000379	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PTHLH—prostate cancer	1.66e-05	0.000376	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTA4—prostate cancer	1.65e-05	0.000375	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—TBXAS1—prostate cancer	1.65e-05	0.000375	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—GSTT1—prostate cancer	1.63e-05	0.00037	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—ACHE—prostate cancer	1.63e-05	0.00037	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—JUP—prostate cancer	1.63e-05	0.000369	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—WNT4—prostate cancer	1.63e-05	0.000369	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP2A6—prostate cancer	1.61e-05	0.000366	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTA2—prostate cancer	1.61e-05	0.000365	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.61e-05	0.000364	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—SULT1A1—prostate cancer	1.59e-05	0.000361	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—ABCG5—prostate cancer	1.59e-05	0.000361	CbGpPWpGaD
Rocuronium—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—prostate cancer	1.58e-05	0.000358	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—AKR1C3—prostate cancer	1.57e-05	0.000356	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—ANXA1—prostate cancer	1.56e-05	0.000354	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PRKACB—prostate cancer	1.56e-05	0.000354	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTA1—prostate cancer	1.55e-05	0.000352	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—RALBP1—prostate cancer	1.55e-05	0.000352	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MC2R—prostate cancer	1.55e-05	0.000352	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP17A1—prostate cancer	1.54e-05	0.00035	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTO1—prostate cancer	1.54e-05	0.000348	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—HSD3B2—prostate cancer	1.54e-05	0.000348	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NAT2—prostate cancer	1.54e-05	0.000348	CbGpPWpGaD
Rocuronium—SLCO1A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.53e-05	0.000346	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.52e-05	0.000345	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PTHLH—prostate cancer	1.51e-05	0.000342	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PRKACB—prostate cancer	1.48e-05	0.000335	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP2C18—prostate cancer	1.47e-05	0.000334	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PLCB2—prostate cancer	1.47e-05	0.000334	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—LRP2—prostate cancer	1.47e-05	0.000334	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—NCOA2—prostate cancer	1.47e-05	0.000334	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—CALCA—prostate cancer	1.46e-05	0.000331	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—P4HB—prostate cancer	1.44e-05	0.000328	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PPP3CA—prostate cancer	1.44e-05	0.000326	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—CXCL12—prostate cancer	1.43e-05	0.000324	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—ANXA1—prostate cancer	1.42e-05	0.000321	CbGpPWpGaD
Rocuronium—SLC22A1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.4e-05	0.000319	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—SLC5A5—prostate cancer	1.4e-05	0.000318	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PENK—prostate cancer	1.38e-05	0.000313	CbGpPWpGaD
Rocuronium—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.37e-05	0.000312	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP2E1—prostate cancer	1.37e-05	0.000311	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—SULT2A1—prostate cancer	1.37e-05	0.00031	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—NQO1—prostate cancer	1.36e-05	0.000307	CbGpPWpGaD
Rocuronium—CHRM2—SIDS Susceptibility Pathways—IL6—prostate cancer	1.35e-05	0.000306	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—MED12—prostate cancer	1.35e-05	0.000305	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GNG5—prostate cancer	1.34e-05	0.000303	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—TH—prostate cancer	1.34e-05	0.000303	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—CALCA—prostate cancer	1.33e-05	0.000301	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.33e-05	0.000301	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP3A4—prostate cancer	1.32e-05	0.0003	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GHR—prostate cancer	1.32e-05	0.000299	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.32e-05	0.000298	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PRKCQ—prostate cancer	1.3e-05	0.000295	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP1B1—prostate cancer	1.3e-05	0.000295	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—CXCL12—prostate cancer	1.3e-05	0.000294	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NCOA3—prostate cancer	1.29e-05	0.000292	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—NRP1—prostate cancer	1.26e-05	0.000287	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—GGT1—prostate cancer	1.26e-05	0.000285	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—NCOA1—prostate cancer	1.24e-05	0.000281	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—HPGDS—prostate cancer	1.23e-05	0.000278	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—ADRB2—prostate cancer	1.23e-05	0.000278	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP19A1—prostate cancer	1.22e-05	0.000277	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP2C19—prostate cancer	1.22e-05	0.000277	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—VAV3—prostate cancer	1.19e-05	0.000271	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTT1—prostate cancer	1.19e-05	0.00027	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—ACHE—prostate cancer	1.19e-05	0.00027	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PRKCQ—prostate cancer	1.18e-05	0.000268	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—RXRA—prostate cancer	1.18e-05	0.000267	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP2A6—prostate cancer	1.18e-05	0.000267	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GNRH1—prostate cancer	1.18e-05	0.000266	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—VIP—prostate cancer	1.18e-05	0.000266	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—ITPR1—prostate cancer	1.16e-05	0.000263	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.15e-05	0.00026	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—AKR1C3—prostate cancer	1.15e-05	0.00026	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PRKACB—prostate cancer	1.14e-05	0.000258	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GRP—prostate cancer	1.14e-05	0.000258	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—LPAR1—prostate cancer	1.14e-05	0.000258	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—COMT—prostate cancer	1.14e-05	0.000258	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—GSTP1—prostate cancer	1.13e-05	0.000256	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP17A1—prostate cancer	1.13e-05	0.000256	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—LRP2—prostate cancer	1.13e-05	0.000255	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PLCB2—prostate cancer	1.13e-05	0.000255	CbGpPWpGaD
Rocuronium—SLC22A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.12e-05	0.000253	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—ITPR1—prostate cancer	1.11e-05	0.000252	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—ADRB2—prostate cancer	1.11e-05	0.000252	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CX3CL1—prostate cancer	1.11e-05	0.000251	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—P4HB—prostate cancer	1.11e-05	0.000251	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.09e-05	0.000248	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—VAV3—prostate cancer	1.08e-05	0.000246	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—HIST1H2BG—prostate cancer	1.08e-05	0.000246	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PDE4D—prostate cancer	1.08e-05	0.000244	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GRB7—prostate cancer	1.08e-05	0.000244	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NCOA2—prostate cancer	1.07e-05	0.000244	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—ITPR1—prostate cancer	1.05e-05	0.000239	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—TYMS—prostate cancer	1.05e-05	0.000238	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—HIST1H4H—prostate cancer	1.05e-05	0.000238	CbGpPWpGaD
Rocuronium—CHRM2—GPCR ligand binding—CXCL8—prostate cancer	1.05e-05	0.000237	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—GSTM1—prostate cancer	1.04e-05	0.000236	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—SLC5A5—prostate cancer	1.03e-05	0.000232	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GNG5—prostate cancer	1.02e-05	0.000232	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—LPL—prostate cancer	1.02e-05	0.000231	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP2E1—prostate cancer	1e-05	0.000227	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NQO1—prostate cancer	9.9e-06	0.000224	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CYP1A1—prostate cancer	9.85e-06	0.000223	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—ERCC2—prostate cancer	9.77e-06	0.000221	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—TH—prostate cancer	9.76e-06	0.000221	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP3A4—prostate cancer	9.66e-06	0.000219	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP1B1—prostate cancer	9.49e-06	0.000215	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GGT1—prostate cancer	9.19e-06	0.000208	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—MTHFR—prostate cancer	9.18e-06	0.000208	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NCOA1—prostate cancer	9.06e-06	0.000205	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PPARA—prostate cancer	9.01e-06	0.000204	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP19A1—prostate cancer	8.93e-06	0.000202	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PTHLH—prostate cancer	8.91e-06	0.000202	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—TGFBR1—prostate cancer	8.91e-06	0.000202	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—AKR1C3—prostate cancer	8.76e-06	0.000199	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PRKACB—prostate cancer	8.72e-06	0.000198	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—RXRA—prostate cancer	8.61e-06	0.000195	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—THBS1—prostate cancer	8.5e-06	0.000193	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PPP3CA—prostate cancer	8.5e-06	0.000193	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CAV1—prostate cancer	8.47e-06	0.000192	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ANXA1—prostate cancer	8.38e-06	0.00019	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—COMT—prostate cancer	8.3e-06	0.000188	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTP1—prostate cancer	8.26e-06	0.000187	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PRKCZ—prostate cancer	8.22e-06	0.000186	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—ITPR1—prostate cancer	8.13e-06	0.000184	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.09e-06	0.000183	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PIK3CG—prostate cancer	8.04e-06	0.000182	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—FGFR4—prostate cancer	7.94e-06	0.00018	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PARP1—prostate cancer	7.94e-06	0.00018	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CALCA—prostate cancer	7.84e-06	0.000178	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PIK3CG—prostate cancer	7.72e-06	0.000175	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—TYMS—prostate cancer	7.68e-06	0.000174	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CXCL12—prostate cancer	7.66e-06	0.000174	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—GSTM1—prostate cancer	7.59e-06	0.000172	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—LPL—prostate cancer	7.45e-06	0.000169	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—INS—prostate cancer	7.3e-06	0.000166	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PIK3CG—prostate cancer	7.3e-06	0.000165	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CASP9—prostate cancer	7.21e-06	0.000164	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CYP1A1—prostate cancer	7.19e-06	0.000163	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—CREBBP—prostate cancer	7.15e-06	0.000162	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—ERCC2—prostate cancer	7.14e-06	0.000162	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PIK3CD—prostate cancer	7.06e-06	0.00016	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—NGFR—prostate cancer	6.99e-06	0.000158	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PRKCQ—prostate cancer	6.99e-06	0.000158	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MAP3K7—prostate cancer	6.91e-06	0.000157	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PIK3CD—prostate cancer	6.78e-06	0.000154	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—MTHFR—prostate cancer	6.71e-06	0.000152	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—FGF10—prostate cancer	6.64e-06	0.000151	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PPARA—prostate cancer	6.58e-06	0.000149	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ADRB2—prostate cancer	6.57e-06	0.000149	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	6.48e-06	0.000147	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	6.46e-06	0.000146	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	6.41e-06	0.000145	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—VAV3—prostate cancer	6.41e-06	0.000145	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—NOS3—prostate cancer	6.4e-06	0.000145	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	6.32e-06	0.000143	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ITPR1—prostate cancer	6.22e-06	0.000141	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CAV1—prostate cancer	6.19e-06	0.00014	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	6.16e-06	0.00014	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—IGF1R—prostate cancer	5.94e-06	0.000135	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	5.92e-06	0.000134	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PIK3CB—prostate cancer	5.91e-06	0.000134	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—JAK2—prostate cancer	5.89e-06	0.000133	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PTGS2—prostate cancer	5.86e-06	0.000133	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—LPL—prostate cancer	5.7e-06	0.000129	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—IL2—prostate cancer	5.65e-06	0.000128	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	5.65e-06	0.000128	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PIK3CG—prostate cancer	5.64e-06	0.000128	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	5.59e-06	0.000127	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ITGB3—prostate cancer	5.5e-06	0.000125	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	5.37e-06	0.000122	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ERBB3—prostate cancer	5.34e-06	0.000121	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—INS—prostate cancer	5.33e-06	0.000121	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—FGFR2—prostate cancer	5.33e-06	0.000121	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—CREBBP—prostate cancer	5.22e-06	0.000118	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—IL2—prostate cancer	5.13e-06	0.000116	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—TERT—prostate cancer	5.12e-06	0.000116	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PTEN—prostate cancer	5.11e-06	0.000116	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PIK3CD—prostate cancer	4.95e-06	0.000112	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—HIF1A—prostate cancer	4.89e-06	0.000111	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—EP300—prostate cancer	4.87e-06	0.00011	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—LEP—prostate cancer	4.78e-06	0.000108	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CAV1—prostate cancer	4.73e-06	0.000107	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—KDR—prostate cancer	4.68e-06	0.000106	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—NOS3—prostate cancer	4.68e-06	0.000106	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ESR1—prostate cancer	4.56e-06	0.000103	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—BAD—prostate cancer	4.45e-06	0.000101	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PIK3CB—prostate cancer	4.32e-06	9.79e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	4.31e-06	9.77e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—APC—prostate cancer	4.31e-06	9.77e-05	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PTGS2—prostate cancer	4.28e-06	9.7e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—EGF—prostate cancer	4.26e-06	9.66e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—IRS1—prostate cancer	4.26e-06	9.66e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—GSK3B—prostate cancer	4.14e-06	9.38e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—INS—prostate cancer	4.08e-06	9.25e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CREBBP—prostate cancer	4e-06	9.06e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—IGF1—prostate cancer	3.95e-06	8.95e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—EGFR—prostate cancer	3.93e-06	8.9e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	3.81e-06	8.65e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	3.79e-06	8.59e-05	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	3.75e-06	8.51e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	3.75e-06	8.5e-05	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PTEN—prostate cancer	3.73e-06	8.46e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—KRAS—prostate cancer	3.71e-06	8.41e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—FGF2—prostate cancer	3.63e-06	8.23e-05	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—PIK3CA—prostate cancer	3.6e-06	8.17e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—NOS3—prostate cancer	3.58e-06	8.11e-05	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—EP300—prostate cancer	3.56e-06	8.07e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—JAK2—prostate cancer	3.48e-06	7.88e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	3.41e-06	7.73e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MDM2—prostate cancer	3.39e-06	7.7e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—ERBB2—prostate cancer	3.35e-06	7.59e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	3.3e-06	7.49e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CXCL8—prostate cancer	3.17e-06	7.2e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	3.1e-06	7.03e-05	CbGpPWpGaD
Rocuronium—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	3.07e-06	6.95e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CASP3—prostate cancer	3.04e-06	6.89e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—IL2—prostate cancer	3.03e-06	6.88e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—IL6—prostate cancer	3.02e-06	6.84e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CCND1—prostate cancer	2.96e-06	6.7e-05	CbGpPWpGaD
Rocuronium—SLCO1A2—Metabolism—AKT1—prostate cancer	2.94e-06	6.67e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	2.93e-06	6.64e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MMP9—prostate cancer	2.87e-06	6.51e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	2.86e-06	6.49e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PTEN—prostate cancer	2.85e-06	6.47e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling by GPCR—AKT1—prostate cancer	2.78e-06	6.31e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—EP300—prostate cancer	2.72e-06	6.17e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—SRC—prostate cancer	2.65e-06	6e-05	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—PIK3CA—prostate cancer	2.63e-06	5.97e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—VEGFA—prostate cancer	2.58e-06	5.84e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—STAT3—prostate cancer	2.55e-06	5.79e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—MYC—prostate cancer	2.37e-06	5.38e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—TGFB1—prostate cancer	2.37e-06	5.36e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—EGFR—prostate cancer	2.32e-06	5.26e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—KRAS—prostate cancer	2.19e-06	4.97e-05	CbGpPWpGaD
Rocuronium—SLC22A1—Metabolism—AKT1—prostate cancer	2.15e-06	4.88e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	2.01e-06	4.56e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—TP53—prostate cancer	1.95e-06	4.42e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—IL6—prostate cancer	1.78e-06	4.04e-05	CbGpPWpGaD
Rocuronium—CHRM2—Signaling Pathways—AKT1—prostate cancer	1.64e-06	3.73e-05	CbGpPWpGaD
